Lataa...
BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML). Although randomized evidence demonstrates that imatinib (a commercially available TKI) prolongs event–free survival in patients with CML, some patients develop imatinib intolerance or resistance. I...
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Public Library of Science
2011
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3001986/ https://ncbi.nlm.nih.gov/pubmed/21188137 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/currents.RRN1204 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|